PFG Investments LLC Has $591,000 Position in Hologic, Inc. (NASDAQ:HOLX)

PFG Investments LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,268 shares of the medical equipment provider’s stock after selling 214 shares during the period. PFG Investments LLC’s holdings in Hologic were worth $591,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of HOLX. Macquarie Group Ltd. increased its holdings in shares of Hologic by 227.2% in the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after purchasing an additional 4,363,687 shares in the last quarter. Norges Bank acquired a new stake in Hologic during the 4th quarter worth $175,900,000. Arrowstreet Capital Limited Partnership grew its holdings in Hologic by 110.6% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,896,174 shares of the medical equipment provider’s stock worth $145,664,000 after acquiring an additional 995,854 shares during the period. Qube Research & Technologies Ltd grew its holdings in Hologic by 117.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,378,258 shares of the medical equipment provider’s stock worth $95,651,000 after acquiring an additional 743,557 shares during the period. Finally, Prudential Financial Inc. grew its holdings in Hologic by 246.0% during the 1st quarter. Prudential Financial Inc. now owns 920,718 shares of the medical equipment provider’s stock worth $70,730,000 after acquiring an additional 654,628 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Transactions at Hologic

In related news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock worth $2,473,443 in the last three months. Insiders own 1.75% of the company’s stock.

Hologic Trading Up 1.5 %

HOLX opened at $77.35 on Thursday. The stock has a market capitalization of $18.16 billion, a P/E ratio of 36.66, a P/E/G ratio of 2.58 and a beta of 1.00. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The firm’s fifty day simple moving average is $74.73 and its 200 day simple moving average is $71.84. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.07 EPS. As a group, research analysts anticipate that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of a number of analyst reports. Raymond James lifted their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. UBS Group lifted their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. Needham & Company LLC lifted their price target on shares of Hologic from $83.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Finally, William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and an average price target of $86.89.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.